Martin M. McGlynn

The Regenerative Medicine Foundation is a non-profit organization that aims to accelerate the development of regenerative medicine to improve health and deliver cures. The non-profit company is based in Winston-Salem, NC. The foundation fosters strategic collaborations to achieve its mission and produces its flagship event, the World Stem Cell Summit. Additionally, the foundation honors leaders in the field through the Stem Cell and Regenerative Medicine Action Awards and promotes educational initiatives.

StemCells, Inc. engages in the research, development and commercialization of stem cell therapeutics and related tools and technologies for academia and industry. The company is focused on developing and commercializing stem and progenitor cells as the basis for novel therapeutics and therapies; and cells and related tools and technologies to enable stem cell-based research and drug discovery and development. StemCells research and development efforts are focused on identifying and developing stem and progenitor cells as potential therapeutic agents. The company was founded by David J. Anderson and Fred H. Gage in August 1988 and is headquartered in Newark, CA.

ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field.

Inflabloc Pharmaceuticals, Inc. engages in the research and development of pharmaceutical treatments. It develops products for the treatment of gastrointestinal disorders and inflammatory diseases. The company was founded in 1991 and is headquartered in Salt Lake City, UT.